TP 122
Alternative Names: TP-122Latest Information Update: 22 Apr 2024
At a glance
- Originator Technophage
- Class Anti-infectives; Bacteriophages
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory tract infections
Most Recent Events
- 17 Apr 2024 Technophage plans the phase I/II RECOVER trial for Ventilator-associated-pneumonia (In adults, In the elderly) in France (Inhalation), in September 2024 (NCT06370598)
- 21 Jan 2022 Technophage files an IND/clinical trial application (CTA) for Respiratory tract infections, prior to January 2022 (Technophage pipeline, January 2022)
- 25 Mar 2021 Technophage plans to file a clinical trial application/IND for Respiratory tract infections (Technophage pipeline, March 2021)